Template for Employer



[Company Letterhead]


[Recipient Name]




Dear [Recipient Name]

Decline of COVID-19 Vaccination

I understand that I have been requested by the company to take the COVID-19 vaccination. I have detailed here my reasons for declining the vaccination. I hope that declining the vaccination would in no way prejudice me in terms of my employment status.

  1. Our Singapore government has made it clear that the vaccine is voluntary. Everyone should decide whether to take it based on their own risk-benefit assessment.
  2. In the Pfizer trials, the vaccine has only been shown to reduce the symptoms of COVID-19, but the vaccines may not prevent transmission or spread of the COVID-19. Hence, if I do not take it, it does not actually pose a risk to other employees (whether they do decide to take it or not).
  3. Pfizer has not finished the final phase 3 trials for the vaccination. It is only slated to end on 27 Jan 2023. As such, the vaccine currently administered is an experimental one. Pfizer is only approved in USA under an Emergency Use Authorization and not been approved by Food and Drugs Administration (FDA). Similarly, Health Sciences Authority (HSA) in Singapore has granted interim authorization under the Pandemic Special Access Route (PSAR). Any person who chooses to take this vaccination is involuntarily subjected as an experimental subject for a trial that I do not consent to partaking.
  4. Both the Pfizer and Moderna vaccines are mRNA vaccines. mRNA vaccines are new inventions and have never been administered on anyone before, let alone on the entire population. Therefore, there has not been any studies on the long-term safety and efficacy of mRNA vaccines.
  5. There has not been studies to determine whether the COVID-19 vaccines could create an effect known as Antibody-Dependent Enhancement (ADE). ADE occurs when a vaccine produces binding antibodies instead of neutralizing antibodies. The binding antibodies help the viruses to enter the cells of organs more easily, and can create more severe symptoms in the vaccinated, including death, when exposed to the actual virus. A dengue vaccine introduced into the Philippines was halted and recalled in 2017 after about 600 children died from ADE caused by the vaccine, despite the vaccine having been already approved by the World Health Organization as being safe. Since the first SARS outbreak in 2003, scientists have been trying to develop a vaccine for SARS. In their development of a vaccine for SARS, ferrets were injected with experimental vaccines and then exposed to the live SARS virus. When examined, the ferrets were found to have developed severe hepatitis indicating liver damage. Since administering a challenge test (exposure to the actual virus) is deemed to be unethical in human trials, it will not be known whether the COVID-19 vaccines could cause ADE in humans.
  6. The adverse effects for the COVID-19 vaccination are not minor, nor are they rare. By 18 December, 112,807 people were injected with the Pfizer/BioNTech vaccine in the U.S. Of these, 3,150 were subsequently unable to perform normal daily activities, unable to work, required care from doctor or health care professional or even hospitalized. This is a severe adverse rate of 2.8%. Of greater concern, reports also indicated deaths and paralysis after the vaccination. Even though these have been chalked up to coincidences, there are too many of them to not warrant caution on my part, especially since the pharmaceutical companies are free from liability of the effects of the vaccines. Even though the government has announced a possible compensation plan for the vaccine-injured, I choose to not take the risk of taking the vaccine.
  7. [Finally, I have allergies of [XXX] or [could be thinking of conceiving in the near future]. Therefore, I belong to the population segment that is not suitable to take this vaccination.]
  8. Thanks for your kind understanding in respecting my right to bodily integrity.


[Your Name]

Please download the letter with list of references on p2.

Credit to author Darius Soon